Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration.
Radium-223 in mCPRC patients: a large real-life Italian multicenter study / Frantellizzi, V., Monari, F., Mascia, M., Costa, R.P., Rubini, G., Spanu, A., Farcomeni, A., Lodi Rizzini, E., Cindolo, L., Tripoli, V., Lavelli, V., Nuvoli, S., Pontico, M., Dionisi, V., Ferrari, C., De Vincentis, G.. - In: MINERVA UROLOGY AND NEPHROLOGY. - ISSN 2724-6442. - Volume 74, Issue 1, Pages 21 - 28 February 2022:(2022). [10.23736/S2724-6051.20.03808-4]
Radium-223 in mCPRC patients: a large real-life Italian multicenter study
Spanu, Angela;Nuvoli, Susanna;
2022-01-01
Abstract
Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration.| File | Dimensione | Formato | |
|---|---|---|---|
|
2022.Minerva Urology Nephrology. Ra223.pdf
solo utenti autorizzati
Tipologia:
Versione editoriale (versione finale pubblicata)
Licenza:
DRM non definito
Dimensione
975.9 kB
Formato
Adobe PDF
|
975.9 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
